Avantor, Inc. (NYSE:AVTR – Get Free Report) EVP James Bramwell sold 3,758 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total value of $65,877.74. Following the completion of the sale, the executive vice president now owns 87,379 shares in the company, valued at approximately $1,531,753.87. This represents a 4.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Avantor Stock Performance
NYSE AVTR traded up $0.22 on Friday, reaching $16.71. The stock had a trading volume of 6,975,650 shares, compared to its average volume of 5,757,332. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.70 and a current ratio of 1.07. Avantor, Inc. has a 12-month low of $16.41 and a 12-month high of $28.00. The business’s 50-day moving average price is $20.60 and its 200 day moving average price is $22.74. The stock has a market cap of $11.37 billion, a P/E ratio of 16.06, a price-to-earnings-growth ratio of 1.55 and a beta of 1.28.
Avantor (NYSE:AVTR – Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same quarter last year, the firm earned $0.22 EPS. As a group, equities analysts expect that Avantor, Inc. will post 1.06 earnings per share for the current year.
Hedge Funds Weigh In On Avantor
Wall Street Analyst Weigh In
Several research firms recently commented on AVTR. Barclays reduced their price objective on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Raymond James reissued an “outperform” rating and issued a $24.00 price objective (down from $26.00) on shares of Avantor in a research note on Monday, February 10th. UBS Group reissued a “neutral” rating and issued a $25.00 price objective (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Wells Fargo & Company reduced their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Finally, Morgan Stanley reduced their price objective on Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.92.
View Our Latest Report on Avantor
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Recommended Stories
- Five stocks we like better than Avantor
- Industrial Products Stocks Investing
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- Learn Technical Analysis Skills to Master the Stock Market
- 5 Best Gold ETFs for March to Curb Recession Fears
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.